Jing Xu

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
    Jing Xu
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA
    Diabetes 58:250-9. 2009
  2. ncbi Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects
    Jing Xu
    Amgen Inc, MS 29 1 A, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Am J Physiol Endocrinol Metab 297:E1105-14. 2009
  3. ncbi Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance
    Clarence Hale
    Department of Metabolic Disorders, Amgen Inc, MS 29 1 A, One Amgen Center Drive, Thousand Oaks, California 91320, USA
    Endocrinology 153:69-80. 2012
  4. ncbi Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling
    Junming Yie
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Chem Biol Drug Des 79:398-410. 2012
  5. ncbi Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice
    Xiaofan Li
    Amgen Inc, 1120 Veterans Blvd, South San Francisco, CA 94080, USA
    FEBS Lett 583:3230-4. 2009
  6. ncbi Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys
    Murielle M Veniant
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, California 91320, USA
    Endocrinology 153:4192-203. 2012
  7. ncbi FGF21 promotes metabolic homeostasis via white adipose and leptin in mice
    Murielle M Veniant
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, California, United States of America
    PLoS ONE 7:e40164. 2012
  8. ncbi FGF21 N- and C-termini play different roles in receptor interaction and activation
    Junming Yie
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA 91320, USA
    FEBS Lett 583:19-24. 2009
  9. ncbi Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes
    Randy Hecht
    Department of Protein Sciences, Amgen Inc, Thousand Oaks, CA, USA
    PLoS ONE 7:e49345. 2012
  10. ncbi An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice
    Shu Chen Lu
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Mol Pharmacol 75:901-7. 2009

Collaborators

  • Yang Li
  • Wei Wang
  • Junming Yie
  • Minghan Wang
  • Xinle Wu
  • Lei Zhou
  • Hui Tian
  • Shuying Liu
  • Wei Gu
  • Jason K Kim
  • Murielle M Veniant
  • Shanaka Stanislaus
  • Randy Hecht
  • Clarence Hale
  • Todd Hager
  • Narumol Chinookoswong
  • Michelle M Chen
  • Xiaofan Li
  • Shu Chen Lu
  • Richard Lindberg
  • Kristoffer S Larsen
  • Jeonghoon Sun
  • Lei Ting Tam
  • Ping Chen
  • Stephen Smith
  • Zhongnan Shen
  • Dwight Winters
  • Ed Belouski
  • Mark Leo Michaels
  • Joan Helmering
  • Yvonne Lau
  • Steven Vonderfecht
  • Allen Sickmier
  • Russell Wada
  • Chris Spahr
  • Renee Komorowski
  • Katherine Winters
  • Thomas Boone
  • Jim Busby
  • Michael Hall
  • David J Lloyd
  • Jennifer Weiszmann
  • Colin Gegg
  • Murielle Veniant
  • David Brankow
  • Shirley Steavenson
  • Hongfei Ge
  • Steven P Gross
  • Silvia Cermelli
  • Zhanyong Shu

Detail Information

Publications12

  1. ncbi Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
    Jing Xu
    Department of Metabolic Disorders, Amgen, Thousand Oaks, California, USA
    Diabetes 58:250-9. 2009
    ..The aims of the current study are to evaluate the role of FGF21 in energy metabolism and to provide mechanistic insights into its glucose and lipid-lowering effects in a high-fat diet-induced obesity (DIO) model...
  2. ncbi Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects
    Jing Xu
    Amgen Inc, MS 29 1 A, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Am J Physiol Endocrinol Metab 297:E1105-14. 2009
    ..We conclude that the acute glucose-lowering and insulin-sensitizing effects of FGF21 are potentially associated with its metabolic actions in liver and adipose tissues...
  3. ncbi Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance
    Clarence Hale
    Department of Metabolic Disorders, Amgen Inc, MS 29 1 A, One Amgen Center Drive, Thousand Oaks, California 91320, USA
    Endocrinology 153:69-80. 2012
    ..We conclude that overt FGF21 resistance was not evident in the disease models, and increased hepatic FGF21 expression as a result of local metabolic changes is likely a major cause of elevated circulating FGF21 levels...
  4. ncbi Understanding the physical interactions in the FGF21/FGFR/β-Klotho complex: structural requirements and implications in FGF21 signaling
    Junming Yie
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, CA 91320, USA
    Chem Biol Drug Des 79:398-410. 2012
    ..Taken together, our data suggest that the D1/linker region regulates both the FGF21/FGFR1c and FGFR1c/β-Klotho interaction, and a direct interaction of FGF21 with FGFR1c may be an important step in receptor-mediated FGF21 signaling...
  5. ncbi Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice
    Xiaofan Li
    Amgen Inc, 1120 Veterans Blvd, South San Francisco, CA 94080, USA
    FEBS Lett 583:3230-4. 2009
    ..These results demonstrate the potential importance of adipocyte lipolysis to the observed acute improvements in plasma parameters...
  6. ncbi Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys
    Murielle M Veniant
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Drive, Thousand Oaks, California 91320, USA
    Endocrinology 153:4192-203. 2012
    ..In conclusion, in more than one species, Fc-FGF21(RG) chronically administered once a week showed similar or greater efficacy than hrFGF21 administered daily...
  7. ncbi FGF21 promotes metabolic homeostasis via white adipose and leptin in mice
    Murielle M Veniant
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, California, United States of America
    PLoS ONE 7:e40164. 2012
    ..Together these data suggest that adipose tissue is required for the triglyceride and glucose, but not the cholesterol lowering efficacy of FGF21, and that leptin and FGF21 exert additive anti-diabetic effects in Tg mice...
  8. ncbi FGF21 N- and C-termini play different roles in receptor interaction and activation
    Junming Yie
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA 91320, USA
    FEBS Lett 583:19-24. 2009
    ..These data demonstrate that the C-terminus of FGF21 is critical for binding to beta-Klotho and the N-terminus is critical for fibroblast growth factor receptor (FGFR) activation...
  9. ncbi Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes
    Randy Hecht
    Department of Protein Sciences, Amgen Inc, Thousand Oaks, CA, USA
    PLoS ONE 7:e49345. 2012
    ..In summary, we engineered a potent and efficacious long-acting FGF21 analog with a favorable pharmaceutical property for potential clinical development...
  10. ncbi An acyl-ghrelin-specific neutralizing antibody inhibits the acute ghrelin-mediated orexigenic effects in mice
    Shu Chen Lu
    Department of Metabolic Disorders, Amgen Inc, One Amgen Center Dr, Thousand Oaks, CA 91320, USA
    Mol Pharmacol 75:901-7. 2009
    ..The lack of long-term effects on body weight control by 33A suggests that compensatory mechanisms may contribute to the regulation of energy balance...
  11. ncbi Co-receptor requirements for fibroblast growth factor-19 signaling
    Xinle Wu
    Amgen Inc, South San Francisco, California 94080, USA
    J Biol Chem 282:29069-72. 2007
    ..These results suggest that a functional FGF19 receptor may consist of FGF receptor (FGFR) and heparan sulfate complexed with either alphaKlotho or betaKlotho...
  12. ncbi BicaudalD actively regulates microtubule motor activity in lipid droplet transport
    Kristoffer S Larsen
    Department of Developmental and Cell Biology, University of California Irvine, Irvine, California, USA
    PLoS ONE 3:e3763. 2008
    ..Nonetheless, it is widely believed that BicD may act to tether dynein to cargos. Here we use a combination of biophysical and biochemical studies to investigate BicD's role in lipid droplet transport during Drosophila embryogenesis...